Sng001 for asthma Jun 13, 2014 · AstraZeneca has announced a global license agreement with Synairgen Plc, an AIM-listed UK company specializing in respiratory diseases, for SNG001, a novel, inhaled interferon beta (IFN-beta) in clinical development for treating respiratory tract viral infections in patients with severe asthma. Center, University of Arizona Health Sciences, Tucson, Arizona USA . " Feb 14, 2021 · The panel is now considering trial of SNG001 to check its “efficacy and safety” for the treatment of patients hospitalised with “moderate Covid-19” symptoms. People with a moderate exacerbation may also require admission if they have factors that warrant a lower threshold for admission, such as:. The results showed SNG001 was well tolerated by patients who have been hospitalised with SARS-CoV-2. 65 mL placebo solution) AstraZeneca has signed an exclusive global licence agreement for rights to Synairgen’s SNG001, an inhaled interferon beta in clinical development for treating respiratory tract viral infections in Nov 12, 2020 · We assessed the efficacy and safety of inhaled nebulised interferon beta-1a (SNG001) for the treatment of patients admitted to hospital with COVID-19. Dec 31, 2022 · Southampton, UK – 27 April 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces its preliminary statement of audited results for the year ended 31 December 2022. After the failure of the development program for asthma, Synairgen began development of SNG001 for respiratory infections in COPD patients. Trial summary: a randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFN-β1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection Type: Interventional Site and lead: Wythenshawe Hospital, Dr Tim Felton; Patient group: All COVID Oct 28, 2023 · Safety and efficacy of inhaled SNG001 (IFN-β1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection: a randomised, double-blind, placebo- (SNG001) in patients with asthma with respiratory viral infections enhances antiviral responses and improves lung function. The compound is currently in clinical development for the treatment of respiratory tract viral infections in patients with severe asthma. Am J Respir Crit Care Med 2014; 190: 145 Nov 19, 2024 · Synairgen plc , announces positive data from its Phase II clinical trial. Jun 12, 2014 · AstraZeneca today announced a global licence agreement with Synairgen Plc, an AIM-listed UK company specialising in respiratory diseases, for SNG001, a novel, inhaled Jun 12, 2014 · AstraZeneca (AZ) has added to its portfolio of respiratory drug candidates after licensing an inhaled interferon beta therapy from Synairgen which is in trials to treat viral Apr 19, 2012 · Synairgen, a drug development company that spun out of the University of Southampton, United Kingdom, has announced positive results of a phase 2 clinical trial of its Nov 12, 2020 · DOI: 10. K. Data from two Phase 2 trials (NCT01126177 and NCT02491684) in patients with asthma Dec 2, 2021 · Inhaled recombinant IFN-β was also investigated in patients with exacerbated asthma due to rhinovirus infection and it was found that it was able to reduce symptom burden, (SNG001) was also found to exert antiviral effects on SARS-COV2 variants (UK, South Africa), in vitro after infecting Vero E6 cells . D. This was a randomized, double-blind, parallel, placebo-controlled trial of IFN-β (SNG001) (Figures 1 and and2) 2) involving patients with a history of URTI-induced exacerbations, to test whether inhaled IFN-β can prevent or attenuate worsening asthma symptoms (defined as a rise in the six-item Juniper Asthma Control Questionnaire [ACQ-6] []) May 30, 2024 · of patients with asthma [12, 13]. Results Of 114 patients treated, 111 (97. In two Phase II trials in asthma, SNG001 improved lung function in patients with a The Phase II evaluation of SNG001 will see the recruitment of up to a maximum of 220 participants across US sites, in a home-based setting, split between SNG001 and placebo, and a positive result Early View Nebulised interferon beta-1a (SNG001) in hospitalised COVID-19: Asthma and Airway Disease Research . The effect of inhaled IFN-β on worsening of asthma symptoms caused by viral infections. A phase 2 RCT in hospitalized adult COVID-19 patients given SNG001 6 MIU for 14 days demonstrated that, compared to placebo, the drug was well tolerated and conferred greater odds of clinical SNG001 for asthma and COPD For asthma and COPD patients, Synairgen’s inhaled SNG001 is being developed as a broad spectrum anti-viral therapy to be taken at the onset of cold (or influenza) symptoms to boost the lungs’ anti-viral defences. 50 randomized in the SNG001 group and 51 in the placebo group. Description: This is a version of the account in the main Impact analysis report to Asthma UK that describes how Asthma UK’s project/fellowship funding played a key pump-priming role Phase I and II trial data have shown that SNG001 activates lung antiviral defences as measured in sputum cells, and that SNG001 has been well tolerated in approximately 280 asthma/COPD/COVID-19 AstraZeneca in-licenses Synairgen's SNG001 as a novel immuno-modulatory therapy for viral-induced exacerbation in asthma. Dec 11, 2024 · SNG001 compared to placebo and additionally that patients who received SNG001 were more than twice as likely to recover from COVID-19 as those on placebo. However, treatment with SNG001 on top of standard of care may have prevented progression to severe disease, but this wasn’t proven. There are 5. SNG001 has the potential to address the urgent need for antiviral therapies for COVID-19 and for future pandemic respiratory Two Phase II clinical trials in asthma showed that inhaled SNG001 treatment activated antiviral pathways in the lung, along with improving lung function in patients with a respiratory viral infection. Am J Respir Crit Care Med 2023;207:A3848 Internet address: www. Nov 12, 2020 · In conclusion, SNG001, a treatment already studied and shown to be well tolerated in patients with asthma and COPD, seems to also be well tolerated in patients admitted to hospital with COVID-19, with a range of Nov 12, 2020 · Study design. ” Richard Marsden, Synairgen CEO, commented: “We're delighted that this truly innovative programme, discovered at the University of Southampton and developed by Synairgen, will be taken forward by Nov 2, 2023 · SNG001 tolerability was a notable secondary outcome. Jun 12, 2014 · AstraZeneca today announced a global licence agreement with Synairgen Plc, an AIM-listed UK company specialising in respiratory diseases, for SNG001, a novel, inhaled interferon beta (IFN-beta) in clinical development for treating respiratory tract viral infections in patients with severe asthma. Jun 12, 2014 · AstraZeneca in-licenses Synairgen's SNG001 as a novel immuno-modulatory therapy for viral-induced exacerbation in asthma. A total of 48 patients received SNG001 and 50 received placebo, leading to a total of 98 patients included in the intention-to-treat analysis (ITT); 75 participants Apr 19, 2012 · This pioneering trial investigated the potential for SNG001 to protect asthmatics from respiratory virus infections, principally the common cold, that can spread to the lung, which are a major cause of worsening asthma symptoms. 9% of treated patients in the placebo and SNG001 groups, Jun 12, 2014 · astrazeneca in-licenses synairgen's sng001 as a novel immuno-modulatory therapy for viral-induced exacerbation in asthma phase iia clinical study to June 12, 2014 02:23 ET | Source: AstraZeneca Jun 27, 2024 · Investor overview. Aim-listed Synairgen has progressed SNG001 to the final stage of clinical trials, with current results indicating Current Status. The intention-to-treat analysis ultimately compared 48 participants who of asthma symptoms caused by viral infections. Synairgen Research is developing SNG-001 as a treatment for Asthma|Influenza, Human|Chronic Obstructive Pulmonary Disease|COVID-19. Background Respiratory viral infections are major drivers of chronic obstructive pulmonary disease (COPD) exacerbations. Dinesh Saralaya's 59 research works with 6,229 citations and 20,228 reads, including: 2363. Am J Respir Crit Care Med, 190 (2014), pp. The trials showed that SNG001 boosts antiviral responses in the lungs, improves lung function and, in more difficult-to-treat patients, provides better asthma control during cold 8 Asthma and Airway Disease Research Center, University of Arizona Health Sciences, Tucson, AZ, USA. Product Description. SNG001 contains Interferon-beta that occurs naturally in the body. org Online Abstracts Issue. Synairgen SNG001 COVID-19 research study at MFT. 11, 12 Inhaled SNG001 has been well tolerated in clinical studies to date involving 230 patients with asthma Jul 26, 2019 · These latest preliminary findings in the two-part Phase 2 study (NCT03570359 or 2017-003679-75) showed a “considerable impact” of these infections on patient-reported measures of COPD symptoms, Synairgen said, compared to measures using this same tool in asthma patients in a separate trial. SNG001 is an inhaled interferon beta (IFN-beta) undergoing clinical development for treating respiratory tract viral SNG001 is a recombinant interferon-β1a formulation delivered to the lungs is associated with worse asthma outcomes and accounts for the majority of greenhouse gas emissions from asthma The route of delivery was selected with the aim of achieving sufficiently high concentrations of interferon-β in the lungs that would result in a robust local antiviral response while limiting systemic exposure to interferon-β, which is associated with flu-like symptoms. There is clearly a need for more medication options for patients with COVID-19 and the results suggest that SNG001 might be effective in this setting, although our results require further May 26, 2020 · Two Phase II clinical trials in asthma showed that inhaled SNG001 treatment activated antiviral pathways in the lung along with improving lung function in patients with a respiratory viral infection. 65 mL of interferon-β1a (SNG001) at a concentration of 12 MIU/mL) and placebo for SNG001 The effect of inhaled IFN-beta on worsening of asthma symptoms caused by viral infections. SNG001 well tolerated in this older Jan 16, 2015 · A total of 147 people with asthma on inhaled corticosteroids with a history of virus-associated exacerbations, were randomized to 14-day treatment with inhaled IFN-β 1a (SNG001) or placebo within 24 hours of developing cold symptoms . In the remaining 168 had asthma. Randomized Controlled Trial. Dec 7, 2021 · In a separate oral session on 6 December, Dr Monk presented data showing that inhaled SNG001 significantly increased interferon beta-dependent antiviral biomarkers in the lungs of asthma and Based on the potent antiviral activity of SNG001 in vitro, Synairgen began investigating the safety and efficacy of SNG001 as a broad-spectrum antiviral in specific patient populations including those with asthma and COPD. In D12. 1016/S2213-2600(20)30511-7 Corpus ID: 226972488; Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial @article{Monk2020SafetyAE, title={Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SNG001 (two pre-filled syringes each of 0. Trial. Sep 28, 2017 · Two Phase 2 trials of Synairgen’s SNG001 to treat respiratory viruses infecting patients with asthma have been completed: SG005 (NCT01126177) and INEXAS (NCT02491684). Highlights (including post period-end) Feb 21, 2022 · Synairgen plc ('Synairgen' or the 'Company') Synairgen announces topline results from Phase 3 SPRINTER trial in patients hospitalised with COVID-19 . Li,f Courtney V. Synairgen Plc is an AIM-listed UK company specialising in respiratory drug development. Main,d Phillip D. Disease. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. atsjournals. 65 mL of interferon-β1a (SNG001) at a concentration of 12 MIU/mL) and placebo for SNG001 (two pre-filled syringes of 0. This pioneering trial investigated the potential for SNG001 (inhaled interferon beta) to protect asthmatics from respiratory virus infections (principally the common cold) that can spread to the lung, which are a major cause of worsening asthma symptoms. This guideline was published in 2019 and amended in 2024 to take account of SIGN 245, developed by the British Thoracic Society (BTS), the National Institute for Health and Care Excellence (NICE) and SIGN. 17 RV-B infections generally cause either mild symptoms or are asymptomatic but can contribute to exacerbations in patients with (SNG001), still€in clinical development. Jul 3, 2023 · Risk factors for RV wheezing illnesses and for progression from RV wheezing to childhood asthma. Synairgen plc. Acute exacerbations of asthma in adults: Emergency - UpToDate Admit people with a moderate asthma exacerbation with worsening symptoms despite initial bronchodilator treatment and/or who have had a previous near-fatal asthma attack. Synairgen plc (‘Synairgen’ or the ‘Company’) Synairgen announces positive data from interim analysis of SNG001 trial in COPD patients. Monk and others published Clinical Development of Inhaled Interferon Beta-1a (SNG001) Asthma worsenings were generally mild and tended to peak at Jun 1, 2021 · IFN-β1a (SNG001, Synairgen) has been tested for safety in asthma patients using a vibrating mesh nebulizer. Dec 4, 2024 · When people with asthma get respiratory virus such as a cold or flu it often increases asthma symptoms. Patients receiving SNG001 also developed fewer new COVID-19 symptoms. ASTRAZENECA IN-LICENSES SYNAIRGEN'S SNG001 AS A NOVEL IMMUNO-MODULATORY THERAPY FOR VIRAL-INDUCED EXACERBATION IN ASTHMA Phase IIa clinical study to ASTRAZENECA IN-LICENSES SYNAIRGEN'S SNG001 May 24, 2021 · SNG001 also showed broad-spectrum antiviral activity in man with clinical efficacy seen in clinical studies conducted in asthma and COPD patients with respiratory viral infection caused by common May 12, 2021 · Phase I and II trial data have shown that SNG001 activates lung antiviral defences as measured in sputum cells, and that SNG001 has been well tolerated in approximately 280 asthma/COPD/COVID-19 Apr 20, 2012 · Shares in Southampton, England-based Synairgen shot up nearly 30% on largely positive mid-stage trial data for its experimental therapy SNG001, which is designed to help protect asthma patients from respiratory infections. 3 SPRINTER: SNG001 still in the running? 4 Nebulised aviptadil “futile” in I-SPY COVID-19 trial 4 Lung transplantation after COVID-19-associated ARDS Regarding asthma, we know that there is a shift in the paradigm indicating that in early and relatively mild asthma, we go further and SNG001 is an inhaled formulation of interferon beta-1a it is currently in Phase II clinical trials for COPD patients. 7% and 92. 145-154. Posting of Report and Accounts and Notice of AGM. SNG001 is an inhaled interferon beta medicine that was originally invented at the University of Southampton, southern asthma and COPD makes them an ideal partner for developing SNG001. Unless I am mistaken, this is an inhaled formulation of interferon Importantly, the fold-changes in sputum Mx1 and OAS1 following administration of SNG001 in Part 1 were consistent with changes in a previous asthma study , suggesting that the administered dose is similarly effective in younger patients with asthma and in older patients with COPD – both of whom are at increased risk from viral infections. Phase IIa clinical study to commence in patients with severe asthma. Giganti,c Michael D. II trial data have shown that SNG001 activates lung antiviral defences as measured in sputum cells, and that SNG001 has been well tolerated in approximately 280 asthma/COPD/COVID-19 patients to date. RD is a Jun 16, 2014 · AstraZeneca announced that it has signed into a global license agreement with Synairgen, a pharmaceutical company focused on respiratory disease, to buy SNG001, a novel immuno-modulatory therapy for viral-induced exacerbation in asthma. Of these, 48 patients received SNG001 and 50 received placebo, and were included in the intention-to-treat population. . SNG001 had a favourable safety profile and key secondary end-points analysis suggested that SNG001 may have impacted progression of COVID-19 to severe disease https://bit. Infections caused by the influenza virus and other Nov 1, 2023 · SNG001 (two pre-filled syringes each of 0. SNG001 supports the immune system by correcting Patients who received SNG001 had greater odds of improvement and recovered more rapidly from SARS-CoV-2 infection than patients who received placebo, On-demand inhaled interferon-beta 1a for the prevention of severe asthma exacerbations: results of the INEXAS phase 2a study. Three-Month Safety and Immunogenicity of Bivalent SARS-CoV-2 Omicron-Containing Booster Vaccines Two Phase II clinical trials in asthma showed that inhaled SNG001 treatment activated antiviral pathways in the lung along with improving lung function in patients with a respiratory viral infection. 7 million in the USA (Centers for Disease Control and Prevention) and it Synairgen plc ('Synairgen' or the 'Company') Synairgen presents detailed analysis of Phase 3 SPRINTER trial evaluating SNG001 in hospitalised COVID-19 patients at ATS 2022 · Post hoc analyses conducted in patient populations at greater risk of progression to severe disease or death suggests that SNG001 may have an important clinical effect on top of standard of care Nov 15, 2020 · “SNG001, a treatment already studied and shown to be well tolerated in patients with asthma and COPD, also seems to be well tolerated in patients admitted to hospital with COVID-19, with a range Jan 29, 2024 · potential of SNG001 as a novel treatment for viral exacerbations in difficult to treat asthma but also a crucial link between viral infection, asthma symptoms and severity of disease. Medical diagnosis of Asthma in a medical record (Service Treatment Records, In clinical trials in asthma and COPD, inhaled interferon beta (SNG001) has been well tolerated and shown to up-regulate lung antiviral defences. Nov 2, 2023 · SNG001 tolerability was a notable secondary outcome. Highlights (including post period-end) astrazeneca in-licenses synairgen's sng001 as a novel immuno-modulatory therapy for viral-induced exacerbation in asthma phase iia clinical study to astrazeneca in-licenses synairgen's sng001 as a novel immuno-modulatory therapy for viral-induced exacerbation in asthma phase iia clinical study to Accessibility: Skip TopNav June 12, 2014 02:23 ET | Source: AstraZeneca PLC AstraZeneca PLC Phillip Monk's 38 research works with 1,366 citations and 2,467 reads, including: 375. Introduction. Fletcher,g Caitlyn McCarthy,c David A. IFN-β Oct 27, 2021 · Monoclonal antibodies targeting IgE, interleukin-4 and -13, and interleukin-5 are effective in treating severe type 2 asthma, but new targets are needed. SNG001 delivers an inhaled formulation of Interferon-beta-1a (INF-beta-1a) to the lungs directly via nebulisation – INF-beta is a naturally occurring protein that controls the body’s antiviral Sep 8, 2020 · Press release. Southampton, UK - 23 December 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein Apr 27, 2023 · Conclusions: SNG001 merits further investigation for treatment of COVID-19 in the home and/or hospital settings. By delivering SNG001 directly into the lungs as an aerosol we aim to boost and/or restore the lungs' antiviral responses to clear the virus and improve patients’ outcomes. 4%) completed 28 days of follow-up. Synairgen CEO Richard Marsden said: "With its strong research focus and extensive experience in respiratory disease, AstraZeneca’s commitment to developing novel medicines for patients with asthma and COPD Nov 13, 2020 · Southampton, UK-based biotech company Synairgen has announced that a small phase 2 trial of its investigational candidate SNG001 supports advancement into phase 3 testing. “SNG001 is an innovative and targeted therapy that has, if successful, the potential to offer a step-change in the treatment of severe asthma, and possibly COPD,” Maarten Kraan, PhD, AstraZeneca’s Nov 14, 2020 · Inhaled SNG001 was administered once daily for 14 days with a 28 days post period follow up. COPD Patients Get Synairgen’s SNG001 for Flu, Colds in Phase 2 Trial In order to be eligible for an asthma VA rating, a veteran must meet three (3) criteria by law: #1. 65 mL of interferon-β1a (SNG001) at a concentration of 12 MIU/mL) The effect of inhaled IFN-beta on worsening of asthma symptoms caused Request PDF | On May 1, 2023, P. The majority of the 280 patients had or were suspected to have an active respiratory viral infection (rhinovirus, influenza, Phillip D Monk, Richard J Marsden, Victoria J Tear, Jody Brookes, Toby N Batten, Marcin Mankowski, Felicity J Gabbay, Donna E Davies, Stephen T Holgate, Ling-Pei Ho, Tristan Clark, Ratko Djukanovic, Tom M A Wilkinson, Inhaled Interferon Beta COVID-19 Study Group SNG001 has been shown to improve lung antiviral defenses, as evaluated in patients with and without respiratory viral infections, by sputum cell antiviral biomarkers. Overall compliance to study medication was high, with ≥13 doses taken by 89. SNG001 contains Interferon-beta that occurs naturally in Dec 31, 2022 · RNS Number : 0538U. Stories of impact interferon-β1a (SNG001) in COPD. Additional file 5 Asthma UK’s project/fellowship funding: account of pump-priming research leading to successful early trials of peptide immunotherapy and potential health gains. Interferon-β is naturally produced in response to viral Jul 20, 2020 · Synairgen had previously announced positive results from a Phase 2 study demonstrating that SNG001 produced statistically significant improvement in asthma patients suffering from a cold compared to placebo. Sections Monica Kraft's 330 research works with 17,247 citations and 5,989 reads, including: SPRINTER: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Determine the Efficacy and Safety of More News. SNG001 supports the immune system by correcting a deficiency which makes patients In Part 1, SNG001 upregulated sputum interferon gene expression. The panel has asked Gurugram-based Paraxel to submit further data for review, which includes details of phase I and II clinical trials of SNG001 in bronchial asthma, COPD and Covid-19. A randomized trial. Outcomes were assessed throughout the treatment period and the subsequent 14-day follow-up period. Synairgen has conducted randomised placebo controlled clinical trials of SNG001 involving >200 asthma and COPD patients. AstraZeneca in-licenses Synairgen’s SNG001 as a novel immuno-modulatory therapy for viral-induced exacerbation in asthma This category of patient is estimated to represent between 10% and 20% of all adult asthma sufferers. Synairgen is also testing SNG001 as a treatment for Asthma, with the trial currently in the second phase, which could yield positive results. Trial Status. May 27, 2020 · Interviewer: Professor Holgate, thank you for taking the time today to discuss the research going into the SNG001 drug as a therapy for COVID-19. Oct 28, 2023 · patients, we have shown that SNG001 boosts lung antiviral defences, as assessed by sputum cell antiviral biomarkers both in patients with and without respiratory viral infections. Am J Respir Crit Care Med 2014; 190: 145 Apr 19, 2012 · This pioneering trial investigated the potential for SNG001 to protect asthmatics from respiratory virus infections, principally the common cold, that can spread to the lung, which are a major cause of worsening asthma symptoms. Jul 7, 2014 · Study Design. 7 million in the USA (Centers for Disease Control and Prevention) and it May 29, 2024 · Importantly, the fold-changes in sputum Mx1 and OAS1 following administration of SNG001 in Part 1 were consistent with changes in a previous asthma study , suggesting that the administered dose is similarly effective in younger patients with asthma and in older patients with COPD – both of whom are at increased risk from viral infections. This respiratory condition is characterized The use of biologics in asthma has been established with the approval of the humanized monoclonal immunoglobulin E-targeted antibody (SNG001; ClinicalTrials. In this study, SNG001 will be given by a nebuliser. These trials have shown that SNG001 has: Synairgen plc ('Synairgen' or the 'Company') Results for the year ended 31 December 2021. Chew,b Mark J. Title: 2023;207:A3848 Mar 18, 2020 · Two Phase II clinical trials in asthma showed that inhaled SNG001 treatment activated antiviral pathways in the lung along with improving lung function in patients with a respiratory viral infection. Synairgen plc (‘Synairgen’ or the ‘Company’) Appointment of New Chairman. In Part 2, there were minimal SNG001–placebo differences in the efficacy endpoints; however, whereas gene expression was Gabbay F, Wark P, Thomson NC, et al. Immunotherapy in lung disease. Patients with ‘difficult to treat' asthma - approximately half of the patients in the trial - benefitted significantly from SNG001 treatment. The company’s shares are trading at lows, last seen in March 2020, and Inhaled anti-viral drug SNG001 has a primary target market in the US and Europe. Am With SNG001, researchers hope to boost the body's antiviral system to fight respiratory infections that tend to worsen COPD symptoms. Synairgen is a specialist respiratory biotech company whose primary focus is developing our investigative inhaled interferon beta candidate (SNG001) for severe viral lung infections . Viral factors. Patients who received SNG001 had greater odds of improvement and recovered more rapidly from SARS-CoV-2 infection than patients who received placebo, providing a strong rationale for further trials. Clinical Trial Results Summary Trial Title: Dec 23, 2022 · Synairgen plc ('Synairgen' or the 'Company') Results from SPRINTER Phase 3 trial published in the European Respiratory Journal Open Research. gov identifier: NCT01126177). 116 were initially screened and 101 were finally enrolled. 27 June 2024. The investigators will test the study medication to find out if it can prevent the virus spreading from the nose to the lungs. Anti-viral responses were obtained according to sputum biomarkers and, based on these results, the protocol of an on-going phase II trial with COPD patients has been adapted to include patients with confirmed SARS-CoV-2 infection and pre-existing Jul 18, 2022 · A subanalysis of the SPRINTER trial suggests that inhaled interferon-β (SNG001) may provide a benefit in the prevention of COVID-19 severe disease or death, despite the trial not meeting its primary endpoint. 101 patients with COVID-19 were randomized 1:1 to inhaled nebulized interferon beta-1a (SNG001) or placebo at nine UK centers. For further enquiries, please contact: Prior to the main part of the trial, 8 COPD patients will take three consecutive daily doses of SNG001 to make sure it is safe in COPD, it has been safely given to about 150 asthma patients up until now. Use of SNG001 has also been investigated in two studies in patients hospi-talised due to Coronavirus Disease 2019 (COVID-19) [14, 15]. Phase two trials of SNG001 have demonstrated an improved Southampton, UK – 17 April 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, will announce its preliminary statement of audited results for the year ended 31 December 2022 on Thursday 27 April 2023. and participation in a scientific discussion about asthma organised by GlaxoSmithKline. Skip to content; Skip to navigation; Skip to footer; Search Menu Search Search Search Close What science can do What science can do. Southampton, UK – 18 September 2024: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that Simon Shaw Research interests include: - Respiratory Medicine - COPD, Asthma, Neonatal Respiratory Distress Syndrome - Lung immunology (SNG001) for the treatment of patients admitted to hospital with Synairgen to Test SNG001 in Trial for COPD Exacerbations Caused by Viruses. Summary of Results. Part 1 assessed the effects of SNG001 on induced sputum antiviral interferon-stimulated gene expression, of patients with asthma [12, 13]. Jun 12, 2014 · AstraZeneca today announced a global licence agreement with Synairgen Plc, an AIM-listed UK company specialising in respiratory diseases, for SNG001, a novel, inhaled interferon beta (IFN-beta) in clinical development for treating respiratory tract viral infections in SNG001 (two pre-filled syringes each of 0. Dec 7, 2021 · In a separate oral session on 6 December, Dr Monk presented data showing that inhaled SNG001 significantly increased interferon beta-dependent antiviral biomarkers in the lungs of asthma and Jun 12, 2014 · Accessibility: Skip TopNav. RV-A and RV-C species viruses are more commonly associated with significant illnesses and wheezing compared to RV-B. The Effect of Inhaled Interferon Beta-1a (SNG001) Treatment Compared to Placebo on Lung Antiviral Biomarkers Rona Beegan's 10 research works with 372 citations and 587 reads, including: Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a Phase IIa clinical study to commence in patients with severe asthma. Synairgen plc (‘Synairgen’ or the ‘Company’) Results for the year ended 31 December 2023. AstraZeneca today announced a global licence agreement with Synairgen Plc, an AIM-listed UK company specialising in respiratory diseases, for SNG001, a novel, inhaled interferon beta (IFN-beta) in clinical development for treating respiratory tract viral infections in patients with severe asthma. UK-based and AIM Jun 12, 2014 · astrazeneca in-licenses synairgen's sng001 as a novel immuno-modulatory therapy for viral-induced exacerbation in asthma phase iia clinical study to June 12, 2014 02:23 ET | Source: AstraZeneca Apr 19, 2012 · The study, which took place at 20 sites, investigated SNG001 in 134 adult asthma patients, representing ‘mild-moderate' through to ‘severe' asthmatics, who caught a cold. Use of SNG001 has also been investigated in two studies in patients hospi-talised due to Coronavirus Disease 2019 (COVID-19) "SNG001 is an innovative and targeted therapy that has, if successful, the potential to offer a step-change in the treatment of severe asthma, and possibly COPD (chronic obstructive pulmonary SNG001 is a recombinant IFNβ for nebulized delivery that is well tolerated in patients with asthma and chronic obstructive pulmonary disease (COPD). This abstract is funded by: Synairgen Research Limited, UK and NIAID. ly/3huTDX9. Jun 12, 2014 · SNG001 also provides the opportunity to expand the clinical programme in other pulmonary diseases including chronic obstructive pulmonary disease. SPRINTER assessed the efficacy and safety of SNG001 in adults hospitalised due to COVID-19 who required Jun 26, 2018 · The drug candidate can promote natural antiviral defense mechanisms that prevent the occurrence of COPD exacerbations. Southampton, UK - 25 May 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces its preliminary statement of audited According to an abstract, a trial investigating SNG001 (inhaled IFN-β) for the prevention or reduction of asthma symptoms after the onset of a respiratory viral infection, have According to an abstract, a trial investigating SNG001 (inhaled IFN-β) for the prevention or reduction of asthma symptoms after the onset of a respiratory viral infection, have shown that SNG001 maintained antiviral response during the treatment period . Southampton, UK – 27 April 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces its preliminary statement of audited results for the year ended 31 December 2022. Jul 20, 2020 · Two Phase II clinical trials in asthma showed that inhaled SNG001 treatment activated antiviral pathways in the lung, along with improving lung function in patients with a respiratory viral infection. Southampton, UK - 21 February 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today Jan 28, 2021 · IFN-β1a (SNG001) Adults, In 2005 Aradigm/APT Pharmaceuticals took a nebulised formulation of HCQ into a PhII asthma study using the Aradigm AERx soft mist device 17. Dec 21, 2022 · SNG001 is a recombinant interferon-β1a formulation delivered to the lungs via nebuliser. Phase. We did a Jun 16, 2014 · AstraZeneca announced that it has signed into a global license agreement with Synairgen, a pharmaceutical company focused on respiratory disease, to buy SNG001, a Apr 20, 2012 · Shares in Southampton, England-based Synairgen shot up nearly 30% on largely positive mid-stage trial data for its experimental therapy SNG001, which is designed to help Apr 19, 2012 · The study, which took place at 20 sites, investigated SNG001 in 134 adult asthma patients, representing ‘mild-moderate' through to ‘severe' asthmatics, who caught a cold. Alternative Names: sng-001, sng001, sng 001 Latest Update: 2023-12-19 Latest Update Note: PubMed Publication. SNG001 supports the immune system by correcting a deficiency Overall, SNG001 was well-tolerated in patients with COPD, and upregulated lung antiviral defences to accelerate viral clearance, and warrant further investigation in a larger study. SNG001 has the potential to address the urgent need for antiviral therapies for COVID19 and for future pandemic respiratory Southampton, UK – 10 October 2024: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces the results of Phase I and II trial data have shown that SNG001 activates lung antiviral defences as measured in sputum cells, and that SNG001 has been well tolerated in approximately 280 asthma/COPD/COVID-19 patients to-date. Jun 12, 2014 · SNG001 is an innovative and targeted therapy that has, if successful, the potential to offer a step-change in the treatment of severe asthma, and possibly COPD. 4 million asthmatics in the UK (Asthma UK) and 25. Nov 12, 2020 · In conclusion, SNG001, a treatment already studied and shown to be well tolerated in patients with asthma and COPD, seems to also be well tolerated in patients admitted to hospital with COVID-19, with a range of clinical outcomes displaying a beneficial pattern of response to SNG001 therapy. Primary Completion Date Apr 19, 2012 · Scientists from the University of Southampton and Synairgen, a respiratory drug development company spun out from the University, can announce positive data from its Phase II clinical trial, into When people with asthma get respiratory virus such as a cold or flu it often increases asthma symptoms. Monk,d Arzhang Cyrus Javan,e Jonathan Z. The objective is to treat and/or attenuate a deterioration of asthma or COPD symptoms, by AstraZeneca has inked a global license agreement with Synairgen, a U. 11,14 In two phase 2 trials, SNG001 had a significantly greater beneficial effect on lung function than placebo in patients with asthma with respiratory infection Jun 12, 2014 · LONDON—AstraZeneca and Synairgen Plc, a United Kingdom-based company that specializes in respiratory diseases, have inked a global license agreement for SNG001, Synairgen’s novel, inhaled interferon beta (IFN-beta). Hughes, cCarlee Moser, Mark J. Itepekimab is a new Nov 22, 2023 · Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial Prasanna Jagannathan,a ,kKara W. Study population and setting. 8. Results showed that SNG001 prevented asthma symptoms from getting worse during the first week SNG001 is a broad-spectrum antiviral offering potential against a range of respiratory viruses, including common cold, flu and coronaviruses, which can lead to critical illness. In the first, patients receiving SNG001 were more likely to improve, and recovered more rapidly, than those receiving placebo [14]. company specializing in respiratory diseases, for SNG001, a novel, inhaled interferon beta (IFN-beta) in clinical development for treating respiratory tract viral infections in patients with severe asthma. Southampton, UK – 27 June 2024: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today The findings of this study suggests that SNG001 could potentially be used in treating patients admitted to hospital with COVID-19, although SNG001 should be explored further in a larger trial. Asthma is a prevalent chronic inflammatory respiratory condition affecting millions of people worldwide and presents substantial challenges in both diagnosis and management. jbje cyyye kbj kcdldcn urbxf wxu vfoz ttishlvf errih qidq